Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $28.01 in the prior trading day, Alkermes plc (NASDAQ: ALKS) closed at $27.81, down -0.71%. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 1.2 million shares were traded. ALKS stock price reached its highest trading level at $28.145 during the session, while it also had its lowest trading level at $27.66.
Ratios:
Our goal is to gain a better understanding of ALKS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.35. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on November 11, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
On September 26, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $44.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Hopkinson Craig C. sold 3,748 shares for $30.00 per share. The transaction valued at 112,447 led to the insider holds 65,740 shares of the business.
Hopkinson Craig C. bought 3,748 shares of ALKS for $112,447 on Dec 03 ’25. On Dec 01 ’25, another insider, Hopkinson Craig C., who serves as the EVP R&D, Chief Medical Officer of the company, sold 4,000 shares for $29.30 each. As a result, the insider received 117,200 and left with 65,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALKS now has a Market Capitalization of 4591917568 and an Enterprise Value of 3552401920. As of this moment, Alkermes’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.76, and their Forward P/E ratio for the next fiscal year is 17.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.02 while its Price-to-Book (P/B) ratio in mrq is 2.65. Its current Enterprise Value per Revenue stands at 2.335 whereas that against EBITDA is 9.139.
Stock Price History:
The Beta on a monthly basis for ALKS is 0.48, which has changed by -0.025739133 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, ALKS has reached a high of $36.45, while it has fallen to a 52-week low of $25.17. The 50-Day Moving Average of the stock is -6.21%, while the 200-Day Moving Average is calculated to be -5.93%.
Shares Statistics:
The stock has traded on average 2.28M shares per day over the past 3-months and 1637150 shares per day over the last 10 days, according to various share statistics. A total of 165.10M shares are outstanding, with a floating share count of 161.42M. Insiders hold about 2.24% of the company’s shares, while institutions hold 103.95% stake in the company. Shares short for ALKS as of 1765756800 were 20033904 with a Short Ratio of 8.78, compared to 1763078400 on 17295320. Therefore, it implies a Short% of Shares Outstanding of 20033904 and a Short% of Float of 17.59.
Earnings Estimates
The stock of Alkermes plc (ALKS) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.38, with high estimates of $0.38 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.22 and $1.43 for the fiscal current year, implying an average EPS of $1.93. EPS for the following year is $2.16, with 2.0 analysts recommending between $2.32 and $2.0.
Revenue Estimates
15 analysts predict $378.57M in revenue for. The current quarter. It ranges from a high estimate of $400.84M to a low estimate of $357M. As of. The current estimate, Alkermes plc’s year-ago sales were $429.99MFor the next quarter, 15 analysts are estimating revenue of $378.72M. There is a high estimate of $418.92M for the next quarter, whereas the lowest estimate is $329.83M.
A total of 15 analysts have provided revenue estimates for ALKS’s current fiscal year. The highest revenue estimate was $1.49B, while the lowest revenue estimate was $1.45B, resulting in an average revenue estimate of $1.47B. In the same quarter a year ago, actual revenue was $1.56BBased on 11 analysts’ estimates, the company’s revenue will be $1.8B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.54B.
